Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6

the team at RHT need appreciation from us shareholders for controlling the expenses like family run businesses. Thinking out of the box as a growth company and slowly but gradually grabbing the share in different segments of healthcare industry . AI scans bring consistent revenue of 4 million per year and now we have drug trials to keep the company cash flow positive. let's hope liver fibrosis scans can be available in 6 months then that will be a game changer for us. Andrew is highly driven professional and I was present in one his presentations to brokers. He won't settle down anything less than 30c in 12 months. Any new deal for drug trial will easily going to push us beyond 12c.